Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period.

Trial Profile

Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs S 18986 (Primary)
  • Indications Mild cognitive impairment
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Status changed from suspended to discontinued.
    • 15 Nov 2010 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 15 Nov 2010 Planned end date changed to 1 May 2006 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top